Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03928288 · ClinicalTrials.gov registry record · Phase 2
Cabergoline for the Treatment of Chronic Pain Due to Endometriosis
A Phase 2 study of Endometriosis, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
- 6
- Study locations
NCT03928288: Completed Phase 2 study of Endometriosis, sponsored by Boston Children's Hospital.
NCT03928288 is a Phase 2 study of Endometriosis that has completed, run by Boston Children's Hospital. The registered enrollment target is 129 participants, below the 262-participant average among 48 other Endometriosis trials with a reported enrollment target (51% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03928288, a Phase 2 study of Endometriosis, has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
- 6
- Study locations
Study Summary
Endometriosis is dependent on angiogenesis (the sprouting of new blood vessels) for its growth and maintenance, but the side effects of currently approved angiogenesis inhibitors make these agents inappropriate for use in reproductive-age patients. This obstacle will be overcome by performing a randomized, double blind clinical trial aimed at repurposing an existing drug, cabergoline, as a safe, alternative angiogenesis inhibitor for adolescents and young women with endometriosis. This trial proposes a novel, non-hormonal, non-surgical therapeutic approach aimed at alleviating the pain and suffering associated with this common chronic disease that currently has limited treatment options.
Primary Outcome
BPI: A 7-item self-report measure. The items in this scale can be grouped into those that assess physical functioning (general activity; walking ability; normal work, including both work outside the home and housework), those that assess emotional functioning (mood; relations with people; enjoyment of life), and a single item that assesses the extent to which pain interferes with sleep. Either the item asking about the "worst pain" or the arithmetic mean of the four severity items can be used as
Conditions Studied
Interventions
- DRUG Cabergoline 0.5 MG
- DRUG Placebo - Cap
Study Locations (6)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Brigham and Women's Hospital - Boston
- Children's Hospital Boston - Boston
California
- Standford University - Palo Alto
Colorado
- Childrens Hospital Colorado - Aurora
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2019-12-02 |
| Est. Completion | 2026-01-14 |
| Phase | Phase 2 |
What the finished NCT03928288 record still lists
NCT03928288 is an interventional study that assigns participants to a tested intervention. The registered 129 participants enrollment target is mid-sized for trials with a published cap, below the 262-participant average among 48 other Endometriosis trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Endometriosis appearing as the primary indexed condition, and to 2 interventions - of which Cabergoline 0.5 MG is the first listed.
NCT03928288 lists 6 locations in 4 states (Massachusetts, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT03928288 about?
NCT03928288 is a clinical study titled "Cabergoline for the Treatment of Chronic Pain Due to Endometriosis". Endometriosis is dependent on angiogenesis (the sprouting of new blood vessels) for its growth and maintenance, but the side effects of currently approved angiogenesis inhibitors make these agents inappropriate for use in reproductive-age patients. This obstacle will be overcome by performing a rand...
What is the current status of trial NCT03928288?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2019-12-02. Estimated completion is 2026-01-14.
What conditions does trial NCT03928288 study?
This clinical trial studies the following conditions: Endometriosis.
What interventions are being tested in trial NCT03928288?
The interventions under investigation include: Cabergoline 0.5 MG (DRUG), Placebo - Cap (DRUG).
Who is sponsoring clinical trial NCT03928288?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03928288 being conducted?
This trial has 6 study locations across California, Colorado, Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometriosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03928288's enrollment target sits among peer trials
129 17th of 48 higher than 32 of 48 other Endometriosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometriosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Endometriosis With 18F-fluorofuranylnorprogesterone PET / MRI
RECRUITING · Phase 2
-
Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis
RECRUITING · Phase 2
-
Proof of Concept Study to Eval MetriDx Lab-developed Test to Identify Endometriosis-specific Bio Markers
RECRUITING · Phase 2
-
Glycemic Regulation as Endometriosis Adjunct Treatment
RECRUITING · Phase 2
-
The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial
COMPLETED · Phase 2
-
Endometriosis Trial: Study of NBI-56418 in Endometriosis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03619850 · 129 participants · Phase 3
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
- NCT05704361 · 129 participants · Phase 1
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
- NCT05919849 · 129 participants · Phase 1
Supporting Parents in Affirming Their Children's Experiences of Stigma
- NCT06313749 · 129 participants · NA
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI